Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children

Archives of Iranian Medicine

Volumn 9, Issue 4, 2006, Pages 308-314

  Siavoshi, Farideh ^a   Safari, Fatemeh ^a   Doratotaj, Danna ^b   Khatami, Gholam Reza ^c   Fallahi, Gholam Hossein ^c   Mirnaseri, Mohamad Mehdi ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adults; Children; Helicobacter pylori; Resistance

Indexed keywords

AGAR; AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DILUTION; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STOMACH BIOPSY; TISSUE CULTURE;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; METRONIDAZOLE; MIDDLE AGED; TETRACYCLINE;

EID: 33751347886     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Goodman KJ, Correa P. The transmission of Helicobacter pylori. A critical review of the evidence. Int J Epidemiol. 1995; 24: 875-887.
2. Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. CMAJ. 1994; 150: 177-185.
3. Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: a consensus statement. European Paediatric Task Force on Helicobacter pylori. J Paediatr Gastroenterol Nutr. 2000; 30: 207-213.
4. Sherman P, Hassall E, Hunt RH, Fallone CA, Veldhuyzen Van Zanten S, Thomson AB, et al. Canadian Helicobacter Study Group Consensus Conference on the Approach to Helicobacter pylori Infection in Children and Adolescents. Can J Gastroenterol. 1999; 13: 553-559.
5. Tolia V. Helicobacter pylori infection in pediatric patients. Curr Gastroenterol Rep. 1999; 4: 308-313.
6. Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull. 1998; 54: 207-216.
7. Raymond J, Kalach N, Bergeret M, Benhamou PH, Barbet JP, Gendrel D, et al. Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children. Antimicrob Agents Chemother. 1998; 42: 1334-1335.
8. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). Antimicrob Chemother. 2000; 46: 1029-1031.
9. Glupczynski Y, Megraud F, Anderson LP, Lopez-Brea M. Antibiotic susceptibility of Helicobacter pylori in Europe in 1998: results of the third multicenter study. Gut. 1999; 45 (suppl 3): A3.
10. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin: influence on treatment outcome. Am J Gastroenterol. 1998; 93: 386-389.
11. Gotoh A, Kawakami Y, Akahane T, Akamatsu T, Shimizu T, Kiyosawa K, et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Microbiol Immunol. 1997; 41: 7-12.
12. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998; 115: 1272-1277.
13. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterol. 1998; 115: 1278-1282.
14. Mukhopadhyay AK, Kersulyte D, Jeong JY, Datta S, Ito Y, Chowdhury A, et al. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J Bacteriol. 2000; 182: 3219-3227.
15. Loo V G, Sherman P, Matlow AG. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother. 1992; 36: 1133-1135.
16. Alizadeh RS, Siavoshi F, Malekzadeh R. Furazolidone antimicrobial effectiveness against metronidazole resistant strains of H.pylori. Eastern Mediterranean Health J 2006; 12: 286-293.
17. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobarter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002; 5: 705-709.
18. Glupczynski Y, Goutier S, van de Borre C. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut. 1995; 37: A56.
19. Liu WZ, Shi Y, Wu SM. Study on short-term triple therapy combining omeprazole, clarithromycin, and furazolidone or metronidazole to eradicate infection of Helicobacter. Shanghai Med J. 1998; 21: 402-403.
20. Kalach N, Bergeret M, Benhamou PH, Dupont C, Raymond J. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol. 2001; 39: 394-397.
21. Wu H, Shi XD, Wang HT, Liu JX Resistance of Helicobacter pylori to metronidazole, tetracycline, and amoxicillin. J Antimicrob Chemother. 2000; 46: 121-123.
22. Boyanova L, Stancheva I, Spassova Z, Katzarov N, Mitov I, Koumanova R. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbial. 2000; 49: 415-441.
23. Dore MP, Sepulveda AR, Mura I. Explanation for variability of omeprazole amoxicillin therapy? Tolerance of H.pylori to amoxicillin. Gastroenterology. 1997; 112: A105.
24. Piccolomini R, Di Bonaventura G, Catamo G. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol. 1997; 35: 1842-1846.
25. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother. 2001; 45: 306-308.
26. Mendonca S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000; 5: 79-83.
27. Coudron PE, Stratton CW. In vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori. J Antimicrob Chemother. 1998; 42: 657-660.
28. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000; 14: 211-215.
29. Xiao SD, Liu WZ, Hu PJ, Xia DH, Tytgat GN. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone, and clarithromycin triple therapy for 1 week. Aliment Pharmacol Ther. 1999; 13: 311-315.
30. Kato S, Fujimura S, Udagawa H, Shimizu T, Maisawa S, Ozawa K, et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol. 2002; 40: 649-653.
31. Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 1985; 49: 1-32.
32. Nikaido H, Normark S. Sensitivity of Escherichia coli to various beta-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic beta-lactamases: a quantitative predictive treatment. Mol Microbiol. 1987; 1: 29-36.
33. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother. 1992; 36: 695-703.
34. Saier MH Jr, Paulsen IT. Phylogeny of multidrug transporters. Semin Cell Dev Biol. 2001; 12: 205-213.
35. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli. J Bacteriol. 1997; 179: 2512-2518.
36. Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, et al. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol. 2000; 182: 3142-3150.
37. Kern WV, Oethinger M, Jellen-Ritter AS, Levy SB. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 2000; 44: 814-820.
38. Rand JD, Danby SG, Greenway DI, England RR. Increased expression of the multidrug efflux genes acrAB occurs during slow growth of Escherichia coli. FEMS Microbiol Lett. 2002; 207: 91-95.
39. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother. 2003; 51: 9-11.
40. Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother. 2000; 44: 248-254.
41. van Amsterdam K, Bart A, van der Ende A. A Helicobacter pylori To1C efflux pump confers resistance to metronidazole. Antimicrob Agents Chemother. 2005; 49: 1477-1482.
42. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996; 40: 477-480.
43. Kwon DH, El-Zaatari FA, Kato M, Osato MS, Reddy R, Yamaoka Y, et al. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother. 2000; 44: 2133-2142.
44. Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004; 57: 37-42.
45. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H, et al. Peptic ulcer disease, irritable bowel syndrome, and constipation in two populations in Iran. Eur J Gastroenterol Hepatol. 1995; 7: 427-433.
46. Mikaeli J, Malekzadeh R, Ziad-Alizadeh B, Nasseri-Mogaddam S, Valizadeh M, Khoncheh R, et al. Prevalence of Helicobacer pylori in two Iranian provinces with high and low incidence of gastric carcinoma. Arch Iranian Med. 2000; 3: 6-9.
47. Buckley N, Morain CO. Helicobacter pylori eradication-a surrogate marker for duodenal ulcer healing. Eur J Gastroenterol Hepatol. 1996; 8: 415.
48. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Masstricht Consensus Report. Gut. 1997; 41: 8-13.
49. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001; 15: 411-416.
50. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004; 19: 89-93.